Metabolites associated with conjugated hyperbilirubinemia and transaminitis in a discovery cohort of 234 pediatric patients treated for ALL at Texas Children’s Hospital, 2007 to 2018
| Metabolite . | OR (95% CI) c.bili . | P value . |
|---|---|---|
| 1,2-Dipalmitoyl-GPC (16:0/16:0) | 5.76 (2.20-23.16) | .002 |
| Octadecenedioylcarnitine (C18:1-DC)∗ | 9.58 (2.60-82.98) | .007 |
| Hexadecanedioate (C16-DC) | 5.36 (1.96-30.05) | .010 |
| Hexadecenedioate (C16:1-DC)∗ | 4.09 (1.71-18.20) | .011 |
| Octadecenedioylcarnitine (C18-DC)∗ | 24.87 (2.30-506.03) | .015 |
| Tetradecanedioate (C14-DC) | 11.09 (2.46-165.54) | .019 |
| Octadecenedioate (C18:1-DC) | 4.06 (1.77-28.55) | .022 |
| Metabolite . | OR (95% CI) c.bili . | P value . |
|---|---|---|
| 1,2-Dipalmitoyl-GPC (16:0/16:0) | 5.76 (2.20-23.16) | .002 |
| Octadecenedioylcarnitine (C18:1-DC)∗ | 9.58 (2.60-82.98) | .007 |
| Hexadecanedioate (C16-DC) | 5.36 (1.96-30.05) | .010 |
| Hexadecenedioate (C16:1-DC)∗ | 4.09 (1.71-18.20) | .011 |
| Octadecenedioylcarnitine (C18-DC)∗ | 24.87 (2.30-506.03) | .015 |
| Tetradecanedioate (C14-DC) | 11.09 (2.46-165.54) | .019 |
| Octadecenedioate (C18:1-DC) | 4.06 (1.77-28.55) | .022 |
Indicates compounds that have not been officially confirmed based on a standard, but the authors are confident in its identity.